$-0.77 EPS Expected for Tonix Pharmaceuticals Holding Corp. (TNXP)

July 14, 2018 - By Anthony Romero

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Logo

Analysts expect Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to report $-0.77 EPS on August, 13.They anticipate $0.12 EPS change or 18.46 % from last quarter’s $-0.65 EPS. After having $-0.88 EPS previously, Tonix Pharmaceuticals Holding Corp.’s analysts see -12.50 % EPS growth. The stock decreased 1.00% or $0.04 during the last trading session, reaching $3.95. About 144,657 shares traded or 10.85% up from the average. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has declined 28.97% since July 14, 2017 and is downtrending. It has underperformed by 41.54% the S&P500.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. The company has market cap of $33.42 million. The Company’s lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder , which is in Phase 3 study in the military-related PTSD population. It currently has negative earnings. The firm is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

More recent Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) news were published by: Benzinga.com which released: “40 Biggest Movers From Friday” on June 18, 2018. Also Benzinga.com published the news titled: “30 Biggest Movers From Yesterday” on July 10, 2018. Benzinga.com‘s news article titled: “28 Stocks Moving In Monday’s Mid-Day Session” with publication date: July 09, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: